Advanced Filters
noise
Found 1,144 clinical trials

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder

18 - 70 years of age All Phase 2
Y Yanghua Tian, PhD

TIS for NSSI in Adolescent Depression

Temporal Interference Stimulation (TIS) has been successfully used to help patients with depression. However, its role in alleviating self injuries remained uncertain. This trial will compare the effectiveness of TIS to a placebo control on non-suicidal self injury (NSSI) in patients with major depressive disorder(MDD).

12 - 22 years of age All Phase N/A
R Roger S. McIntyre, MD, FRCPC

Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder

This study will look at how a new medication (dextromethorphan and bupropion taken together in one pill) affects the brain in people with depression. All participants will take the medication for two weeks and have brain scans done. Since people with depression often feel reduced enjoyment in day-to-day activities, our …

18 - 65 years of age All Phase 2
D Dang Minh Ly, MD

Accelerated Versus Standard Intermittent Theta Burst Stimulation for Major Depressive Disorder

This randomized, rater-blinded clinical trial aims to compare the effectiveness, safety, and tolerability of accelerated intermittent theta burst stimulation (iTBS) with standard iTBS in adults with major depressive disorder (MDD). Participants will be randomly assigned in a 1:1 ratio to receive either accelerated or standard iTBS targeting the left dorsolateral …

18 - 65 years of age All Phase N/A
S Sinéad Quinn

Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium

The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif eXternally powered Cortical Stimulation (XCS) System when used as indicated for treatment-resistant depression (TRD).

22 - 85 years of age All Phase N/A
D Daniel P. Moriarity, PhD

Precision Depression Adalimumab Trial

The goal of this clinical trial is to learn if the anti-inflammatory medication adalimumab improves depressive symptoms in adults with Major Depressive Disorder (MDD) who are already taking the anti-depressant medication Lexapro (escitalopram). The main questions it aims to answer are: Does adalimumab improve the symptoms of some patients with …

18 years of age All Phase 2
S Stephanie Ellickson, PhD

Tracking Response to Antidepressants in Advance of Investigational Trials

TRAIT is an open-label observational study to evaluate treatment response to selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs) among individuals meeting criteria for Major Depressive Disorder (MDD) and seeking enrollment in investigational trials.

18 years of age All Phase N/A

A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder

The purpose of this study is to assess the efficacy, safety and tolerability of ALKS 7290 following oral administration in adult participants with Major Depressive Disorder.

18 - 65 years of age All Phase 2
E Ezio Cigognetti

Implementation of a Multiple Intervention to Promote Healthy Lifestyles in Patients With Depression

This clinical trial aims to investigate whether an integrative approach combining education on the Mediterranean diet and physical activity (PA) can significantly reduce depressive symptomatology in individuals with major depressive disorder. The study will evaluate changes in depressive symptoms and assess biological modulations, including alterations in the gut microbiota and …

55 - 80 years of age All Phase N/A
P Prem Ganesh, MS

Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101

In this pilot study, investigators aim to combine D-cycloserine, lurasidone, and single-day repeated intermittent Theta Burst Stimulation (iTBS) to preliminarily assess clinical improvement in an open-label cohort and monitor for adverse events over a 6-week follow-up period.

18 years of age All Phase 0

Simplify language using AI